Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-09 09:03 am Purchase |
2024-02-08 | 13G | Enliven Therapeutics, Inc. ELVN |
FMR CORP | 5,902,265 14.321% |
1,482,684 (+33.55%) |
Filing History |
| 2024-02-07 12:16 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
BML Investment Partners, L.P. | 50,000 0.100% |
50,000 (New Position) |
Filing History |
| 2024-02-02 4:15 pm Sale |
2024-01-31 | 13D | Enliven Therapeutics, Inc. ELVN |
5AM Ventures VI L.P. | 4,660,975 11.300% |
-700,563 (-13.07%) |
Filing History |
| 2023-08-28 4:15 pm Sale |
2023-08-24 | 13D | Enliven Therapeutics, Inc. ELVN |
5AM Ventures VI L.P. | 5,361,538 13.000% |
-436,937 (-7.54%) |
Filing History |
| 2023-05-10 09:45 am Purchase |
2023-05-09 | 13G | Enliven Therapeutics, Inc. ELVN |
FMR CORP | 4,419,581 10.749% |
4,419,581 (New Position) |
Filing History |
| 2023-04-27 10:00 am Purchase |
2023-04-18 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 2,124,625 5.170% |
2,124,625 (New Position) |
Filing History |
| 2023-04-24 4:05 pm Purchase |
2023-04-14 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 2,082,123 5.100% |
633,483 (+43.73%) |
Filing History |
| 2023-03-13 4:01 pm Purchase |
2023-03-03 | 13G | Enliven Therapeutics, Inc. ELVN |
Venrock Healthcare Capital Partners III L.P. | 2,214,142 5.400% |
2,214,142 (New Position) |
Filing History |
| 2023-03-06 4:11 pm Purchase |
2023-02-23 | 13G | Enliven Therapeutics, Inc. ELVN |
Citadel Advisors LLC | 2,298,756 5.600% |
2,298,756 (New Position) |
Filing History |
| 2023-03-06 4:00 pm Purchase |
2023-02-23 | 13D | Enliven Therapeutics, Inc. ELVN |
5AM Ventures VI L.P. | 5,798,475 14.100% |
5,798,475 (New Position) |
Filing History |
| 2023-02-28 4:05 pm Purchase |
2023-02-23 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 1,448,640 3.500% |
1,448,640 (New Position) |
Filing History |
| 2023-02-28 4:00 pm Purchase |
2023-02-23 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 8,949,339 21.800% |
8,949,339 (New Position) |
Filing History |
| 2023-02-27 4:57 pm Purchase |
2023-02-23 | 13G | IMARA Inc. IMRA |
RA Capital Management, L.P. | 2,122,465 5.200% |
1,309,784 (+161.17%) |
Filing History |
| 2023-02-21 4:05 pm Purchase |
2023-02-15 | 13G | IMARA Inc. IMRA |
Commodore Capital LP | 710,189 10.800% |
86,490 (+13.87%) |
Filing History |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | IMARA Inc. IMRA |
RA Capital Management, L.P. | 812,681 12.400% |
7,475 (+0.93%) |
Filing History |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | IMARA Inc. IMRA |
Commodore Capital LP | 623,699 9.500% |
249,221 (+66.55%) |
Filing History |
| 2023-02-08 4:16 pm Purchase |
2023-02-08 | 13G | IMARA Inc. IMRA |
BML Investment Partners, L.P. | 834,444 12.700% |
39,444 (+4.96%) |
Filing History |
| 2022-10-24 4:43 pm Purchase |
2022-10-14 | 13G | IMARA Inc. IMRA |
RA Capital Management, L.P. | 805,206 12.250% |
805,206 (New Position) |
Filing History |
| 2022-10-24 4:31 pm Purchase |
2022-10-13 | 13G | IMARA Inc. IMRA |
Commodore Capital LP | 374,478 5.700% |
374,478 (New Position) |
Filing History |
| 2022-05-24 5:11 pm Sale |
2022-05-23 | 13D | IMARA Inc. IMRA |
New Enterprise Associates 14, L.P. | 0 0.000% |
-480,212 (Position Closed) |
Filing History |